Water soluble camptothecin derivatives

Details Water soluble camptothecin derivatives Water soluble camptothecin derivatives

1994-06-10

1996-09-24

Berch, Mark L.

Organic compounds -- part of the class 532-570 series

Organic compounds

Nitrogen attached directly or indirectly to the purine ring...

540599, 540553, 540575, 544 60, 544125, 544377, 546 41, 546196, 549362, 549436, 548240, 5483117, 5483644, 548146, 548526, 548950, 548964, C07D49122, A61K 3147

Patent

active

055592350

ABSTRACT:
The present invention relates to water soluble, camptothecin derivatives of formula (I), ##STR1## wherein: 1) R.sup.1 and R.sup.2 represent independently, hydrogen, lower alkyl, C.sub.3-7)cycloalkyl, C.sub.3-7)cycloalkyl lower alkyl, lower alkenyl, hydroxy lower alkyl, lower alkoxy lower alkyl;

REFERENCES:
patent: 4399276 (1983-08-01), Miyasakawa
patent: 4473692 (1984-09-01), Miyasakawa
patent: 4545880 (1985-10-01), Miyasakawa
patent: 4778891 (1988-10-01), Tagawa et al.
patent: 4894456 (1990-01-01), Uall
patent: 4943579 (1990-07-01), Vishnuvajjala
patent: 4981968 (1991-01-01), Wall et al.
patent: 5049668 (1991-09-01), Wall et al.
patent: 5053512 (1991-10-01), Wani et al.
Muggia, et al., Canc. Chemo. Reports, 56, No. 4,515 (1972).
Gottlieb et al., Canc. Chemo. Reports, 54, No. 6, (1970).
Jaxel, et al., Cancer Research, 49, 1465 (1989).
Giovanella, et al., Cancer, 52, 1146 (1983).
Boven, et al., The Nude Mouse in Oncology Research, CRC Press, Boca Raton, FL (1991).
Fiebig, Human Tumor Xenographs in Anticancer Drug Dev., "Comparison of Tumor Response in Nude Mice and in Patients," Winograd, et al., Eds., ESO Monographs, Springer, Heidelberg, 25 (1988).
Giovanella, et al., Science, 246, 1046 (1989).
Wani et al., J. Med. Chem., 30, 2317-2319 (1987).
Wani et al., J. Med. Chem., 29, 2359 (1986).
March, Advanced Organic Chem., 3rd Ed, pp. 179, John Wiley & Sons, NY (1925).
Lehninger, A., Priniples of Biochem., 813, Worth Publishers, NY (1982).
Kingsbury, et al., J. Med. Chem., 34, 98 (1991).
Lui, F., CRC Critical Review in Biochem., 1-24, 15 (1983).
Vosberg, H., Current Topics in Microbic. and Immu., 19, Springer-Verlag, Berlin (1985).
Wani et al., j. Med. Chem., 23, 554-560 (1980).
Sugasawa, et al., J. Org. Chem., 44, No. 4,578 (1979).
Wall and Wani, Ann. Rev. Pharmacol, Toxical, 17, 117 (1977).
Abbott, Cancer Treatment Reports, 60, No. 8, 1007 (1976).
Schultz, Chem. Rev., 73, No. 4, 385 (1973).
Wani et al., J. Am. chem. Soc., 99, 3631 (1972).
Bissery M C, Mathieu-Boue, A, Lavelle, F. Preclinical evolution of CPT-11, a camptothecin derivative. Proc Am. Assoc. Cancer Res. 32:402, 1991.
Fukuoka, M, Nitani, H, Suzuki, A, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer J. Clin. Oncol. 10: 16-20, 1992.
Negoro, S, Fukuoka, M, Masuda, N, et al. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-- small-cell lung cancer. J. Natl. Cancer Inst. 83:1164-1168, 1991a.
Negoro, S, Fuikuoka, M, Niitani, H, Taguchi T. Phase II study of CPT-11, a new camptothecin derivative, in small cell lung cancer (SCLC). Proc. Am. Soc. Clin. Oncol. 10:241, 1991.
Rothenberg, M L, Kuhn, J., Burris, H. A., Morales, M. T., Nelsoon, J., Eckardt, J. R., Rock, M. K., Terada, K I, Von Hoff, D. D.: A phase I and pharmacokinetic trial of CPT-11 in patients with refractory solids tumors. Proc. Am. Soc. Clin. Oncol. 11:113, 1992.
Rowinsky, E, Grochow, L, Ettinger, D, et al Phase I and pharmacologic study of CPT-11, a semisynthetic topoisomerase I targeting agents, on a single dose schedule, Proc. Am. Soc. Clin. Oncol. 11:115, 1992.
Shimada, Y, Yoshino, M, Wakui, A, et al. Phase II study of CPT-11, a new camptothecin derivative, in the patient with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 10:135, 1991.
Takeuchi, S, Takamizawa, H, Takeda, T, et al. Clinical study of CPT-11, camptothecin derivative, for a gynecological malignancy. Proc. Am. Soc. Clin. Oncol. 10:189, 1991.
Rotherberg, M. L., Eckardt, J. R., Burris, H. A. III, Nelson, J, Kuhn, J. G., Chen, S. F., Hilsenbeck, S. G., Clark, G. M., Fields, S. M., Rodriguez, G. I., Weiss, Gr. R., Smith, L. S., Thurman, A. M., Eckhardt, S. G., Rinaldil, D. A., Perez, E., Von Hoff, D. D.: Irinotecan 9CPT-11) as second-line therapy for patients with 5-FU-refractory colorectgal cancer. Proc. Am. Soc. Clin. Oncol. 13:198, 1994.
Rothenberg, M L, Kuhn, J. G., Burris, H. A., III, Nelson, J, Eckardt, J. R., Tristan-Morales, M I, Hilsenbeck, S. G., Weiss, G. R., Smith, L. S., Rodriguez, G. I., Rock, M. K., Terada, K., Von Hoff, D. D.: A phase I and pharmacokinetic trial of weekly CPT-11. J. Clin. Oncol. 11:2194-2204, 1993.
Wall J. G., Burris, H. A. III, Von Hoff, D. D., Rodriquez, G., Kneuper-Hall, R., Shaffer, D., O'Rourke, T I;, Brown, T., Weiss, G., Clark, G., McVea, S., Brown, J., Johnson, R., Friedman, C., Smith, B, Mann, W, Kuhn, J.: A phase I clinical and pharmacolkinetic study of the topoisomerase I inhibitor topotecan (SKF 104864) given as an intravenous bolus every twenty-one days., Anti-Cancer Drugs 2: 337-345, 1992.
Haas, N B, LaCreta, F P, Walczak, J, et al, Phase I/ pharmacolkinetic trial of topotecan on a weekly 24-hour infusional schedule. Proc. Am. Assoc. Cancer Res. 333:523, 1992.
Kingsbury W D, Hertzberg R P, Beuhm, T C, et al. Clinical synthesis and structure-activity relationships related to SKF 104864, a novel water-soluble analog of camptothecin. Proc. Am. Assoc. Cancer Res. 30:622, 1989.
Rowinsky, E, Grochow, L, Hendricks, C, et al. Phase I and pharmacologic study of topotecan (SKF 104864): A novel topoisomerase I inhibitor. Proc. Am. Soc. Clin. Oncol. 10:93, 1991.
Ten Bokkel Huinink W W, Rodenhuis, S, Beijnen, J. Phase I study of the topoisomerase I inhibitor topotecan (SKF 104864-A). Proc. Am. Soc. Clin. Oncol. 11:110, 1992.
Tuhnjun, R K, McCabe, L, Fancetto, L F, et al. SKF 104864, a water soluble analog of camptothecin with broad-spectrum activity in prelinical tumor models. Proc. Am. Assoc. Cancer Res. 30:623, 1989.
Moertel C G, Schutt, A J, Reitemeier R J, Hahn, R G. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep. 56:95-101, 1972.
Von Hoff, D D, Rozencweig, M, Soper, W T, et al. Commentary: Whatever happened to NSC ? Cancer Treat Rep. 81:759-768, 1977.
Giovanella, B C, Stehlin, J S, Wall, M E, et al. DNA Topoisomerase I-Targeted Chemotherapy of Human Colon Cancer in Xenografts, Science 246:1646-1648 1989.
Hsiang Y-H, Hertzberg, R, Hect, S, Liu, L F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 260: 14873-14878, 1985.
Hsiang, Y-H, Liu L F. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 48:1722-1726, 1988.
Scheithauer, W, Clark, G M, Moyer, M P, Von Hoff, D D.: New screening system for selection of anticancer drugs for treatment of human colorectal cancer. Cancer Res. 46: 2703-2708, 1986.
Staquet, M J, Byar, D P, Green S B, et al. Clinical predicitivity of transplantable tumor systems in the selection of new drugs for solid tumors: rationale for a three stage strategy. Cancer Treat Rep 67:753-765, 1983.
Giovanella, B. C. New Perspectives in Colon Cancer Chemotherapy, Diseases of the Colon and Rectum, 37 (2 Suppl); S96-9, Feb. 1994.
D. S. Martin, Caneer Treat. Rep 68, 1317 (1984).
Estey, Cancer Treat, Rep. 70, 1105 (1986).
Kolata, N. Y. T. Jul. 26, 1994, p. C3 (1994).
Derner, Biol Technology, 12 Mar. 1994, p. 320.
Marsoni, Cancer Treat, Rep 11, 71 (1987).

Affiliated with

Also associated with

Rating

Water soluble camptothecin derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Water soluble camptothecin derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Water soluble camptothecin derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1929494